Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Total Non-Current Liabilities: 2014-2025

Historic Total Non-Current Liabilities for Viridian Therapeutics, Inc.\DE (VRDN) over the last 10 years, with Sep 2025 value amounting to $71.6 million.

  • Viridian Therapeutics, Inc.\DE's Total Non-Current Liabilities rose 15.01% to $71.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.6 million, marking a year-over-year increase of 15.01%. This contributed to the annual value of $68.5 million for FY2024, which is 44.38% up from last year.
  • According to the latest figures from Q3 2025, Viridian Therapeutics, Inc.\DE's Total Non-Current Liabilities is $71.6 million, which was up 10.00% from $65.1 million recorded in Q2 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Total Non-Current Liabilities peaked at $71.6 million during Q3 2025, and registered a low of $14.3 million during Q3 2021.
  • In the last 3 years, Viridian Therapeutics, Inc.\DE's Total Non-Current Liabilities had a median value of $54.6 million in 2025 and averaged $53.1 million.
  • The largest annual percentage gain for Viridian Therapeutics, Inc.\DE's Total Non-Current Liabilities in the last 5 years was 162.80% (2022), contrasted with its biggest fall of 7.96% (2022).
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Total Non-Current Liabilities (Quarterly) stood at $14.8 million in 2021, then surged by 162.80% to $38.9 million in 2022, then increased by 22.03% to $47.4 million in 2023, then spiked by 44.38% to $68.5 million in 2024, then rose by 15.01% to $71.6 million in 2025.
  • Its Total Non-Current Liabilities was $71.6 million in Q3 2025, compared to $65.1 million in Q2 2025 and $54.6 million in Q1 2025.